Evidence map›Paper›PMID 29678162›Full record

ArticleBMC neurology2018

Tacrolimus-induced parkinsonism in a patient after liver transplantation - case report.

Karin Gmitterová, Michal Minár, Miroslav Žigrai, Zuzana Košutzká, Alice Kušnírová, Peter Valkovič

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Neurotoxicity of Calcineurin Inhibitors.Annals of Indian Academy of Neurology · 2025
    Article
  4. Tacrolimus-induced Parkinsonism.Journal of neurology · 2024
    Article
  5. Review
  6. Review
  7. Movement Disorders and Liver Disease.Movement disorders clinical practice · 2021
    Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Karin GmitterováSecond Department of Neurology, Comenius University, Limbova 5, 833 05, Bratislava, Slovakia. gmitterova.karin@gmail.com.
Michal MinárSecond Department of Neurology, Comenius University, Limbova 5, 833 05, Bratislava, Slovakia.
Miroslav ŽigraiFirst Department of Internal Medicine, Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia.
Zuzana KošutzkáSecond Department of Neurology, Comenius University, Limbova 5, 833 05, Bratislava, Slovakia.
Alice KušnírováSecond Department of Neurology, Comenius University, Limbova 5, 833 05, Bratislava, Slovakia.
Peter ValkovičSecond Department of Neurology, Comenius University, Limbova 5, 833 05, Bratislava, Slovakia.
Comenius University Bratislava · SKSlovak Medical University · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatic encephalopathy may manifest by a wide spectrum of neuropsychiatric symptoms, including cognitive impairment, seizures or extrapyramidal symptoms. The liver transplant can lead to improvement of the signs of encephalopathy but subsequent immunosuppressive treatment might possess pronounced neurotoxicity. CASE PRESENTATION: We present a case report of a patient with chronic liver disease who developed signs of Parkinsonism after an orthotopic liver transplant, with consecutive immunosuppressant treatment with tacrolimus. Despite the improvement of liver functions due to the cytostatic treatment, a progressive worsening of neuropsychiatric symptoms associated with the presence of tremor was observed. Metabolic as well as endocrine dysfunctions were excluded as the primary causes of this condition. A brain CT did not reveal structural pathology. Signs of severe, symmetric Parkinsonism - with resting tremor, bradykinesia, rigidity and severe postural instability were observed. A brain MRI was performed with the presence of T2- hyperintensities in basal ganglia bilaterally. Tacrolimus blood concentration was elevated; hence the dose was reduced and later switched to less toxic sirolimus. Subsequently, clinical signs markedly improved after treatment modification. Improvement of clinical symptomatology after tacrolimus discontinuation supports the drug-induced etiology of this neurological condition.

conclusionsCytostatic treatment after solid organ transplantation often leads to signs of encephalopathy. If necessary, the dose of cytostatics needs to be reduced, or a less toxic agent must be chosen for the therapy. This modification is usually efficient with no further need for neurological intervention.

Indexed as

Liver TransplantationParkinsonian DisordersFemaleHumansImmunosuppressive AgentsMiddle AgedTacrolimusImmunosuppressive AgentsTacrolimusImmunosupressive therapyLiver transplantationParkinsonismSirolimusTacrolimus

Identifiers

PMID29678162
PMCPMC5909232
OpenAlexW2801456472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.